See more : EnerTeck Corporation (ETCK) Income Statement Analysis – Financial Results
Complete financial analysis of Kiromic BioPharma, Inc. (KRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kiromic BioPharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Park Hotels & Resorts Inc. (0KFU.L) Income Statement Analysis – Financial Results
- McDowell Holdings Limited (MCDHOLDING.NS) Income Statement Analysis – Financial Results
- Hengdeli Holdings Limited (3389.HK) Income Statement Analysis – Financial Results
- ABB India Limited (ABB.NS) Income Statement Analysis – Financial Results
- E-World Co.,Ltd. (084680.KS) Income Statement Analysis – Financial Results
Kiromic BioPharma, Inc. (KRBP)
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| Gross Profit | -2.80M | -2.07M | -469.80K | -200.00K | -87.50K | -80.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 9.62M | 13.92M | 11.37M | 5.05M | 1.20M | 1.42M |
| General & Administrative | 10.31M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Selling & Marketing | -2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.52M | 17.19M | 13.94M | 14.14M | 2.50M | 1.76M |
| Other Expenses | 0.00 | 0.00 | 53.40K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 17.14M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Cost & Expenses | 19.94M | 31.11M | 25.31M | 19.20M | 3.71M | 3.18M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | -1.85M | 166.50K | 12.20K | 3.30K | 22.50K | 633.10K |
| Depreciation & Amortization | 2.80M | 2.07M | 469.80K | 200.00K | 87.50K | 80.90K |
| EBITDA | -16.30M | -32.50M | -25.74M | -19.00M | -3.62M | -3.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -19.94M | -31.11M | -25.74M | -19.20M | -3.71M | -3.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.01M | -3.62M | 147.00K | -3.30K | -22.50K | -633.10K |
| Income Before Tax | -20.95M | -34.73M | -25.59M | -19.20M | -3.73M | -3.82M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 3.45M | 65.60K | 3.30K | 22.50K | -80.24K |
| Net Income | -21.29M | -38.18M | -25.65M | -19.20M | -3.75M | -3.82M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| EPS Diluted | -21.41 | -70.12 | -67.40 | -79.08 | -29.00 | -32.40 |
| Weighted Avg Shares Out | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
| Weighted Avg Shares Out (Dil) | 1.10M | 544.53K | 380.61K | 242.83K | 129.32K | 117.76K |
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial.
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #CART--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports early efficacy results showing primary lung tumor stabilization and the complete disappearance of brain metastases in the second patient in the Company's Deltacel-01 Phase 1 clinical trial....
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Virginia Oncology Associates, PC (Norfolk, Virginia) has been activated as the second clinical trial site in the Phase 1 Deltacel-01 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic,...
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC...
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
HOUSTON--(BUSINESS WIRE)---- $KRBP #GDT--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces continued encouraging clinical findings from the most recent follow-up visit of the first patient enrolled in Deltacel-01, the Company's Phase 1 clinical trial evaluating Deltacel™ for the...
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)---- $KRBP #Celltherapy--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable early efficacy results from the first patient enrolled in the Phase 1 Deltacel-01 clinical trial with Deltacel™ for treating stage 4 metastatic non-small cell lung cancer...
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
HOUSTON--(BUSINESS WIRE)---- $KRBP #BIOTECH--Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial.
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer.
Kiromic BioPharma Announces Uplisting to OTCQB Market
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma Announces Uplisting to OTCQB Market.
Kiromic BioPharma Announces Deltacel™ Phase 1 Clinical Trial Enters Patient Recruitment Phase at Beverly Hills Cancer Center
HOUSTON--(BUSINESS WIRE)-- #CART--Kiromic BioPharma, Inc. (OTC PINK: KRBP) (“Kiromic” or the “Company”), a clinical-stage, fully-integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence and data mining platform to develop cell therapies with a focus on immuno-oncology, announces the Deltacel™ Phase...
Source: https://incomestatements.info
Category: Stock Reports